Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer Patients' chest fluid: can a Clot-Buster help drain it?

NCT ID NCT01580618

Disease control Sponsor: Kaiser Permanente Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a drug called TNK (tenecteplase) could help drain loculated (pocketed) fluid from the chest in cancer patients better than a saltwater solution. The trial planned to enroll about 20 adults with cancer and a chest tube already in place. However, the study was terminated early, so the findings are limited and not conclusive.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tenecteplase (TNK)
What this could lead to
If it works, this could offer a way to better drain fluid pockets in the chest for cancer patients, potentially reducing discomfort and the need for more invasive procedures.
What could go wrong
The trial was terminated early and enrolled only 20 people, so results are very limited. TNK can also increase the risk of bleeding complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

20 people

The number who actually took part.

Start date

Jan 2008

Finished

Sep 2011

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ability to provide written informed consent and comply with study assessments for the full duration of the study. * Age \> 18 years * Adult, non-gravid patients with malignancy and symptomatic loculated pleural effusion who has undergone percutaneous drainage will be eligible to participate. A loculated effusion is defined as an effusion whose contents cannot be completely drained at the time of initial catheter placement as documented by the initial imaging guided procedure or within 48 hours of catheter placement by chest radiography. Malignant cells need not be found within the pleural fluid. Exclusion Criteria: * Active internal bleeding, involving intracranial and retroperitoneal sites, or the gastrointestinal, genitourinary, or respiratory tracts * History of stroke within 3 months * Intracranial neoplasm, arteriovenous malformation, or aneurysm. * Uncorrectable bleeding diathesis (INR \> 1.5 despite therapy) * Recent intracranial or intraspinal surgery or trauma * Pregnancy (positive pregnancy test) * Severe uncontrolled hypertension * Documented empyema * Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated * Participation in another simultaneous medical investigation or trial * Participation in another clinical investigation within previous 30 days of catheter placement * Prior enrollment in the study * Known allergy to TNK or any of its components

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Malignancy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm Pleural Effusion

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pleural effusion

Contacts and locations

Locations

  • Kaiser Foundation Hospital

    Honolulu, Hawaii, 96819, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.